EMBioSys

EMBioSys

医疗设备制造业

An impactful non-pharmacological intervention for triple-negative breast cancer

关于我们

EMBioSys is developing a platform based technology of non-contact, electrode-free therapeutic wearable garments that utilize inherently safe induced electric fields (iEF Therapy) for treatment of solid metastatic cancers. Our market entry product will consist of wearable garments for treatment of metastatic breast cancer, and more specifically triple-negative breast cancer. iEF Therapy results in significantly improved patient outcomes by hindering metastasis, shrinking the volume and weight of the primary tumor, improving the efficacy of standard of care chemotherapy agents, and boosting the patient’s natural immune response to attack the primary tumor while preventing metastasis.

网站
https://www.embiosys.com/
所属行业
医疗设备制造业
规模
2-10 人
类型
私人持股
创立
2022

EMBioSys员工

动态

  • 查看EMBioSys的公司主页,图片

    125 位关注者

    Thank you to Venture Forum for a great pitch competition, and an opportunity to showcase EMBioSys' important mission to improve treatment outcomes for breast cancer.

    查看Venture Forum的公司主页,图片

    783 位关注者

    ?? What an incredible night at the Venture Forum's 5-Minute Pitch Competition! Congratulations to Nick Gronda, Founder and CEO of Croi, Inc. for taking first place in the Competition and to the runner up Chris Barron, Founder and CEO of EMBioSys. They both had outstanding pitches! We also want to recognize the efforts of all the competitors who pitched their ventures to the audience and judges. Each entrepreneur brought their passion and excitement to the stage and managed to get their messages across in under 5 minutes. The entrepreneur's pitches were unique and compelling, and we are excited to see where they go next! This event wouldn't have been possible without the generous support of our sponsors: ?? Presenting Sponsor: Auxilium Worcester ?? Supporting Sponsors: Masis Staffing Solutions and Off The Rails Worcester ?? Reception Sponsors: Avidia Bank, The Wire Group, and WPI i3 Lab A special shoutouts to the amazing staff at Off the Rails for their hard work and willingness to help. They made everything easy for us. To the entrepreneurs, mentors, judges, and everyone who came out to cheer on the incredible ideas shared last night—thank you for making this event a success. Together, we’re building a stronger, more innovative entrepreneurial community in Central MA. #Innovation #Entrepreneurship #Startups #PitchCompetition #VentureForum #WorcesterMA

    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
  • 查看EMBioSys的公司主页,图片

    125 位关注者

    查看Chris Barron的档案,图片

    Co-Founder and CEO at EMBioSys | Improving patient outcomes for Triple Negative Breast Cancer

    I am thrilled to be participating next week, Thu 11/14 in #NEMIC's 2024 HealthTech Pitch Night & Showcase!?Come watch me pitch and stop by our table to network over complimentary?refreshments. REGISTER TO ATTEND:?https://lnkd.in/ecdSkQWg Date: Thursday, November 14th Time: 4:00 - 7:00 PM Location: Venture Cafe Providence, 225 Dyer Street Providence RSVP via link above

    • 该图片无替代文字
  • 查看EMBioSys的公司主页,图片

    125 位关注者

    EMBioSys is honored to announce that our President and Chief Scientific Officer, Dr. Vish Subramaniam, has been asked to present at the Cancer Bioelectricity Conference sponsored by the National Cancer Institute on September 12th, 2024. Dr. Subramaniam will be speaking about "Technologies for treatment of Metastatic Solid Tumors", including EMBioSys' iEF Therapy.?One of the key goals of the conference is to disseminate the science of bioelectricity and its potential applications towards cancer treatments to a diverse audience.?The National Cancer Institute's support for research and development of bioelectricity is an important step in the evolution of life-saving technologies for cancer patients in the future. https://lnkd.in/epmXvpUF

  • 查看EMBioSys的公司主页,图片

    125 位关注者

    EMBioSys is excited to present at LSI USA 2025!

    查看LSI的公司主页,图片

    22,332 位关注者

    We're just 4 weeks away from LSI Europe '24, but the buzz is already building amongst leading investors, strategics, and innovators for LSI USA '25 in Dana Point, California. After reviewing applications from global leaders working to build breakthrough Medtech and Healthtech businesses, we're revealing the first 100 Innovators selected to present at the event March 17th - 21st in 2025. Here's a sneak peek at 10 of them: ? Jamal RushdyArcuro Medical ? Jenny Hoffmann, PhDBiorithm ? James DacombeCoMind ? Danguole AltmanCx Precision Medicine, Inc. ? Chris BarronEMBioSys ? Codi Amir Gharagouzloo, Ph.DImaginostics ? Yoonho KimMagnendo Corp. ? Theadora James, MHANavigate Maternity ? Chris WoodReveal-Dx ? Alex Jiao — Scout Stay tuned for more innovator and investor announcements, and get in touch with our team to secure your spot at LSI USA '25. Our hotel room block at the Monarch Beach Resort is already nearing capacity and is expected to sell out well in advance. Secure your spot today to ensure you get the best rate and secure a hotel room onsite before they’re sold out.

    • 该图片无替代文字
  • 查看EMBioSys的公司主页,图片

    125 位关注者

    We are honored to announce that Dr. Silvia C. Formenti, MD has joined our Advisory Board! Dr. Formenti is Chair of the Department of Radiation Oncology at Weill Cornell Medicine, and Radiation Oncologist-in-Chief at NewYork-Presbyterian Hospital. She is a recognized leader in cancer research, experienced in translating preclinical work into clinical trials in metastatic breast cancer, lung cancer, and melanoma.

  • 查看EMBioSys的公司主页,图片

    125 位关注者

    EMBioSys is pleased to announce that Tracey Wielinski has joined our Advisory Board. Tracey is a Regulatory, Clinical and Quality executive with 30 years of experience in the Medical Device and Pharmaceutical space focused on strategic, global product realization and compliant business processes. We are looking forward to having Tracey on the team to advise us, as we move towards clinical trials.

  • 查看EMBioSys的公司主页,图片

    125 位关注者

    We are excited to announce that Rick Clemon has joined our Advisory Board! Rick is a CFO with 30 years of experience spanning diverse sectors, including development and clinical-stage life science and medical device companies advancing research and development across pharmaceuticals, biologics, therapies, and assistive technologies focused on cancers, retinal disease, and kidney disease. Rick's wisdom, enthusiasm, and passion for our mission will surely be a tremendous asset as EMBioSys moves towards clinical trials in humans.

  • 查看EMBioSys的公司主页,图片

    125 位关注者

    We are trilled to announce that Jennifer Herron has joined EMBioSys as an Independent Board Director and Strategic Advisor! Jennifer's dedication to our mission is humbling, and we are grateful for her guidance and passion.

    查看Jennifer Herron的档案,图片

    Founder @ BioSpark | Biotech Strategic Acceleration

    I’m happy to share that I’m starting a new position working with the Team at EMBioSys as an Independent Board Member and Strategic Advisor!

    此处无法显示此内容

    在领英 APP 中访问此内容等

  • 查看EMBioSys的公司主页,图片

    125 位关注者

    We are honored to announce that Joe Camardo, MD has officially joined EMBioSys as a Medical Advisor. Joe is a Board Certified General Internist with 30 years of drug development experience in multiple areas, including oncology, inflammation, vaccines, neuroscience, and roles as head of clinical research and medical affairs. Since our iEF therapy potentiates standard of care including chemotherapy, Joe's experience will surely help us navigate the fastest path to market, and saving lives.

  • 查看EMBioSys的公司主页,图片

    125 位关注者

    EMBioSys is excited to announce that we have received a Small Business Innovation Research (SBIR) Phase 1 Award from the National Cancer Institute for Development of a Wearable, Non-invasive, Treatment Device for Metastatic Triple-Negative Breast Cancer (TNBC). We are grateful to the NIH/NCI in recognizing the potential of our therapeutic induced electric field (iEF) technology towards improving treatment outcomes and potentiating standard of care for treatment of solid metastatic cancers. We look forward to collaborating with our research partners at The Ohio State University on this award.

相似主页